Lu sur http://onlinelibrary.wiley.com/wol1/doi ... 2/abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study
Anirban Gupta MD, DM, Vinay Goyal MD, DM*, Achal Kumar Srivastava MD, DM, Garima Shukla MD, DM andMadhuri Behari MD, DM
Version of Record online: 16 AUG 2016
Azathioprine (AZA) is commonly used in myasthenia gravis (MG). Treatment may be prolonged, entailing significant risks and avoidable costs.
We reviewed remission, relapse, and side-effect profiles in MG patients on AZA during treatment and after tapering off. We conducted an ambispective study and analyzed remission, relapse rates, and side-effect profiles in 117 MG patients on AZA.
Thirty-nine patients (33.3%) achieved remission, and 36 (30.8%) achieved complete stable remission (CSR), with a 33% relapse rate. No AZA side effects were seen in 95 (81%) patients. Only duration of disease of >10 years (odds ratio 9.5, 95% confidence interval 2.4–36.9, P = 0.001) was significantly associated with remission. Conclusions: AZA is well tolerated by MG patients, and about 30% go into CSR on long-term AZA